Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TXN | P10599 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439546 | 0.94 | TBXAS1 (0.51) | TBXAS1TERTTAAR1GPR84ALOX15 | |
| SCHEMBL27232031 | 0.93 | TBXAS1 (0.54) | TBXAS1TERTTAAR1GPR84ALOX15 | |
| SCHEMBL4129898 | 0.93 | TBXAS1 (0.54) | TBXAS1TERTTAAR1GPR84ALOX15 | |
| SCHEMBL441513 | 0.88 | TERT (0.47) | TBXAS1TERTTAAR1ALOX15TXN | |
| Iodide SCHEMBL14645279 | 0.86 | TERT (0.46) | TBXAS1TERTTAAR1ALOX15TXN | |
| SCHEMBL10763709 | 0.85 | TBXAS1 (0.46) | TBXAS1TERTTAAR1ALOX15TXN | |
| SCHEMBL9777191 | 0.81 | TBXAS1 (0.60) | TBXAS1TERTTAAR1ALOX15HTR1A | |
| SCHEMBL3431746 | 0.81 | TBXAS1 (0.66) | TBXAS1TERTTAAR1ALOX15HTR1A | |
| SCHEMBL31617011 | 0.80 | TERT (0.39) | TBXAS1TERTTAAR1HRH4 | |
| SCHEMBL28062565 | 0.79 | TBXAS1 (0.69) | TBXAS1TERTTAAR1ALOX15HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3756666-A1 | NICOTINAMIDE COMPOUND FOR USE IN THE TREATMENT OF CANCER | Oncotartis Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3087051-B1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | ONCOTARTIS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20160347748-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC. | 2016-12-01 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2015100322-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120157701-A1 | PROCESS FOR PREPARING SILOXY CARBOXYLATES | BASF SE (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023933-A1 | METHOD FOR ISOLATING ACIDS FROM CHEMICAL REACTION MIXTURES BY USING 1-ALKYLIMIDAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| CN-1894174-A | Method for isolating acids from chemical reaction mixtures by using 1-alkylimidazoles | BASF AG (DE) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | TBXAS1 1025/4885TERT 1263/4885TAAR1 1575/4885 |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | TBXAS1 1864/4885TERT 597/4885TAAR1 3426/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | TBXAS1 1025/4885TERT 1263/4885TAAR1 1575/4885 |
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | NAMPT, NNT, NADK | TBXAS1 1142/4885TERT 1402/4885TAAR1 4024/4885 |
| US-20160347748-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | NAMPT, NNT, NADK | TBXAS1 1142/4885TERT 1402/4885TAAR1 4024/4885 |
| US-20090023933-A1 | METHOD FOR ISOLATING ACIDS FROM CHEMICAL REACTION MIXTURES BY USING 1-ALKYLIMIDAZOLES | POLL, INO80C, BRD7 | TBXAS1 2094/4885TERT 1193/4885TAAR1 2735/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | TBXAS1 1025/4885TERT 1263/4885TAAR1 1575/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | TBXAS1 1013/4885TERT 1954/4885TAAR1 1120/4885 |
| US-20120157701-A1 | PROCESS FOR PREPARING SILOXY CARBOXYLATES | IDH3A, IDH1, HDAC3 | TBXAS1 4428/4885TERT 2450/4885TAAR1 2500/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | TBXAS1 1864/4885TERT 597/4885TAAR1 3426/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | TBXAS1 1013/4885TERT 1954/4885TAAR1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.